- Broad and clinically important benefits beyond the initial registrational endpoints are now reported.
- Durability of clinical effect was seen across multiple outcome measures and findings were consistent across both pivotal Phase 3 trials.
- A single dose of rimegepant, without any rescue medications, was superior to placebo for pain freedom and pain relief at 2 hours post-dosing, and showed a profile of increasing improvement throughout the first eight hours that was sustained compared to placebo out to 24 and 48 hours.
- The vast majority of rimegepant treated patients did not take rescue medications during the 24 hour period after dosing.
- Rimegepant-treated patients showed improvement on measures of functional disability with a greater proportion of patients achieving normal function.
- Rimegepant demonstrated a safety profile similar to placebo including liver function tests.
- Tolerability profile with rimegepant was similar to placebo and favorable compared to historical triptan experience.
- More than 3x the number of subjects who responded to treatment preferred rimegepant over their previous therapy.
PR Newswire
LOS ANGELES, April 22, 2018
